Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)

NCT03824704 is registered in ClinicalTrials.gov with pharmaand GmbH as lead sponsor.

NCT NCT03824704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03824704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)
Lead sponsor
pharmaand GmbH
Phase
Phase 2
Overall status
Terminated
Start date
August 23, 2019
Completion date
August 24, 2020
Enrollment
1 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

endometrioid adenocarcinoma, epithelial ovarian cancer, fallopian tube cancer, high grade serous carcinoma, primary peritoneal carcinoma